Cargando…

How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?

This study aimed to: (1) estimate the disease burden of herpes zoster (HZ) and (2) assess the potential public health impact of introducing adjuvanted recombinant zoster vaccine (RZV) compared with no vaccination in adults aged ≥50 years in Argentina, Brazil, Mexico, Chile, and Colombia using the ZO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Ru, Gomez, Jorge A., de Veras, Bruna, Pinto, Thatiana, Guzman-Holst, Adriana, Nieto, Javier, van Oorschot, Désirée A. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Zoster
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026900/ https://www.ncbi.nlm.nih.gov/pubmed/36821856 http://dx.doi.org/10.1080/21645515.2022.2164144

Ejemplares similares

Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
por: Giannelos, Nikolaos, et al.
Publicado: (2023)

Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer
por: Curran, Desmond, et al.
Publicado: (2023)

Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster
por: Ulaszewska, Marta, et al.
Publicado: (2023)

The incidence of herpes zoster in China: A meta-analysis and evidence quality assessment
por: Zhang, Zhujiazi, et al.
Publicado: (2023)

Hospitalization burden related to herpes zoster infection during the COVID-19 pandemic in Spain (2020-2021)
por: Irigoyen-Mansilla, Victor-Manuel, et al.
Publicado: (2023)

Proceedings of the expert consensus group meeting on herpes zoster disease burden and prevention in India: An opinion paper
por: Ramasubramanian, V, et al.
Publicado: (2023)

How to manage herpes zoster ophthalmicus
por: Tuft, Stephen
Publicado: (2020)

Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme
por: van Oorschot, Desirée A M, et al.
Publicado: (2019)

Estimated Public Health Impact of the Recombinant Zoster Vaccine
por: Patterson, Brandon J., et al.
Publicado: (2021)

The impact of COVID-19 and catch-up strategies on routine childhood vaccine coverage trends in Latin America: A systematic literature review and database analysis
por: Castrejon, María M., et al.
Publicado: (2022)

Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older
por: Shiragami, Makoto, et al.
Publicado: (2019)

Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany
por: Curran, Desmond, et al.
Publicado: (2021)

2300. Incidence, Complications, and Recurrence of Herpes Zoster in Unvaccinated Adults ≥50 Years of Age
por: Ackerson, Bradley, et al.
Publicado: (2019)

Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old
por: Van Oorschot, Desirée, et al.
Publicado: (2018)

Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live
por: Curran, Desmond, et al.
Publicado: (2019)

The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged ≥ 50 Years in Japan: Results of a Markov Model Analysis
por: Watanabe, Daisuke, et al.
Publicado: (2018)

Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults
por: McGirr, Ashleigh, et al.
Publicado: (2019)

The Epidemiology of Herpes Zoster in Immunocompetent, Unvaccinated Adults ≥50 Years Old: Incidence, Complications, Hospitalization, Mortality, and Recurrence
por: Tseng, Hung Fu, et al.
Publicado: (2020)

Laboratory-based surveillance in Latin America: attributes and limitations in evaluation of pneumococcal vaccine impact
por: Nieto Guevara, Javier, et al.
Publicado: (2021)

Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model
por: Patterson, Brandon J, et al.
Publicado: (2020)

Meta-Regression of Herpes Zoster Incidence Worldwide
por: Curran, Desmond, et al.
Publicado: (2021)

Herpes zoster epidemiology in Latin America: A systematic review and meta-analysis
por: Bardach, Ariel Esteban, et al.
Publicado: (2021)

A systematic literature review of herpes zoster incidence worldwide
por: van Oorschot, Désirée, et al.
Publicado: (2021)

Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older
por: Curran, Desmond, et al.
Publicado: (2019)

19. Completion of Two-Dose Recombinant Zoster Vaccine Series in Adults 50 Years and Older
por: Tseng, Hung-Fu, et al.
Publicado: (2020)

1440. Meta-regression Analysis of Worldwide Herpes Zoster Incidence
por: Yawn, Barbara P, et al.
Publicado: (2021)

Economic burden of herpes zoster in Latin America: A systematic review and meta-analysis
por: Javier Balan, Dario, et al.
Publicado: (2022)

Preventing Varicella-Zoster: Advances With the Recombinant Zoster Vaccine
por: Ilyas, Sahrish, et al.
Publicado: (2020)

1156. Real-World Effectiveness of Recombinant Zoster Vaccine in Chinese Adults Aged ≥50 Years in the US
por: Florea, Ana, et al.
Publicado: (2023)

Assessment of the potential public health impact of Herpes Zoster vaccination in Germany
por: Curran, Desmond, et al.
Publicado: (2017)

Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older
por: Cunningham, Anthony L, et al.
Publicado: (2018)

Epidemiology of Varicella Zoster Virus and Herpes Zoster Virus in Gulf Cooperation Council Countries: A Review of the Literature
por: Badur, Selim, et al.
Publicado: (2022)

8. The Adjuvanted Recombinant Zoster Vaccine (RZV) Confers Long-term Protection Against Herpes Zoster: Interim Results of an Extension Study (ZOSTER-049) of Two Clinical Trials (ZOE-50 and ZOE-70)
por: Boutry, Céline, et al.
Publicado: (2020)

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination
por: Bruxvoort, Katia J, et al.
Publicado: (2022)

Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing
por: Lee, Christa, et al.
Publicado: (2021)

07. Recombinant Zoster Vaccine (RZV) Second-Dose Completion in Adults Age 50‒64 Years in the United States
por: Leung, Jessica, et al.
Publicado: (2021)

Burden of Disease of Gonorrhoea in Latin America: Systematic Review and Meta-analysis
por: Bardach, Ariel, et al.
Publicado: (2023)

Healthy ageing: Herpes zoster infection and the role of the adjuvanted recombinant zoster vaccine
por: Curran, D, et al.
Publicado: (2022)

A Cross-Sectional Concept Elicitation Study to Understand the Impact of Herpes Zoster on Patients’ Health-Related Quality of Life
por: Van Oorschot, Desirée, et al.
Publicado: (2022)

The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials
por: Kim, Joon Hyung, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_esbqd608i7og2erv7doflkthfu